Animal and cellular models for hypolipidemic drugs

Bibliography

• Tailleux A, Torpier G, Mezdour H, et al. Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis. Trends Pharmacol Sci 2003;24:530-4
   PubMed Web of Science ®Google Scholar
• Vu-Dac N, Chopin-Delannoy S, Gervois P, et al. The nuclear receptors peroxisome proliferator-activated receptor α and Rev-erbα mediate the species-specific regulation of 3. apolipoprotein A-I expression by fibrates. J Biol Chem 1998;273:25713-20
   PubMed Web of Science ®Google Scholar
• Paigen B, Morrow A, Brandon C, et al. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 1985;57:65-73
   PubMed Web of Science ®Google Scholar
• Funatsu T, Kakuta H, Takasu T, et al. Experimental model of postprandial hypertriglyceridemia in sucrose-fed rats and the effectiveness of atorvastatin in the model. Metabolism 2003;52:609-15
   PubMed Web of Science ®Google Scholar
• Burnett JR, Watts GF. Therapeutic considerations for postprandial dyslipidaemia. Diabetes Obes Metab 2001;3:143-56
   PubMed Web of Science ®Google Scholar
• Zadelaar S, Kleemann R, Verschuren L, et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007;27:1706-21
   PubMed Web of Science ®Google Scholar
• Breslow JL. Mouse models of atherosclerosis. Science 1996;272: 685-8
   PubMed Web of Science ®Google Scholar
• Cullen P, Baetta R, Bellosta S, et al. for the MAFAPS Consortium. Rupture of the atherosclerotic plaque: does a good animal model exist? Arterioscler Thromb Vasc Biol 2003;23:535-42
   PubMed Web of Science ®Google Scholar
• Chakrabarti R, Vikramadithyan RK, Misra P, et al. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol 2003;140:527-37
   PubMed Web of Science ®Google Scholar
• Grand-Perret T, Bouillot A, Perrot A, et al. SCAP ligands are potent new lipid-lowering drugs. Nat Med 2001;7:1332-8
   PubMed Web of Science ®Google Scholar
• Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004;10:1344-51
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294:2581-6
   PubMed Web of Science ®Google Scholar
• Ishibashi S, Brown MS, Goldstein JL, et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993;92:883-93
   PubMed Web of Science ®Google Scholar
• Maxwell KN, Breslow JL. Adenoviral-mediated expression of PCSK9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci USA 2004;101:7100-5
   PubMed Web of Science ®Google Scholar
• Kourimate S, Le May C, Langhi C, et al. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/Kexin type 9. J Biol Chem 2008;283:9666-73
   PubMed Web of Science ®Google Scholar
• van den Maagdenberg AM, Hofker MH, Krimpenfort PJ, et al. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem 1993;268:10540-5
   PubMed Web of Science ®Google Scholar
• van Vlijmen BJ, van den Maagdenberg AM, Gijbels MJ, et al. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 1994;93:1403-10
   PubMed Web of Science ®Google Scholar
• Delsing DJ, Offerman EH, van Duyvenvoorde W, et al. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation 2001;103:1778-86
   PubMed Web of Science ®Google Scholar
• Zadelaar AS, Boesten LS, Jukema JW, et al. Dual PPARα/γ agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice. Arterioscler Thromb Vasc Biol 2006;26:2560-6
   PubMed Web of Science ®Google Scholar
• Sullivan PM, Mezdour H, Quarfordt SH, et al. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse apoE with human APOE*2. J Clin Invest 1998;102:130-5
   PubMed Web of Science ®Google Scholar
• Wouters K, Shiri-Sverdlov R, van Gorp PJ, et al. Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice. Clin Chem Lab Med 2005;43:470-9
   PubMed Web of Science ®Google Scholar
• Shiri-Sverdlov R, Wouters K, van Gorp PJ, et al. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J Hepatol 2006;44:732-41
   PubMed Web of Science ®Google Scholar
• Watanabe Y. Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL-rabbit). Atherosclerosis 1980;36:261-8
   PubMed Web of Science ®Google Scholar
• Kita T, Nagano Y, Yokode M, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 1987;84:5928-31
   PubMed Web of Science ®Google Scholar
• Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987;84:7725-9
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Haudenschild CC, Nickerson C, et al. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-31
   PubMed Web of Science ®Google Scholar
• Booth RF, Martin JF, Honey AC, et al. Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Atherosclerosis 1989;76:257-68
   PubMed Web of Science ®Google Scholar
• Donetti E, Fumagalli R, Paoletti R, et al. Direct antiatherogenic activity of isradipine and lacidipine on neointimal lesions induced by perivascular manipulation in rabbits. Pharmacol Res 1997;35:417-22
   PubMed Web of Science ®Google Scholar
• Soma MR, Donetti E, Parolini C, et al. Effect of lacidipine on the carotid intimal hyperplasia induced by cuff injury. J Cardiovasc Pharmacol 1994;23(Suppl 5):S71-4
   PubMed Web of Science ®Google Scholar
• Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther 2006;111:893-908
   PubMed Web of Science ®Google Scholar
• Yancey PG, Bortnick AE, Kellner-Weibel G, et al. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003;23:712-19
   PubMed Web of Science ®Google Scholar
• Wang N, Silver DL, Thiele C, et al. ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem 2001;276:23742-7
   PubMed Web of Science ®Google Scholar
• Aiello RJ, Brees D, Bourassa PA, et al. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol 2002;22:630-7
   PubMed Web of Science ®Google Scholar
• van Eck M, Bos IS, Kaminski WE, et al. Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc Natl Acad Sci USA 2002;99:6298-303
   PubMed Web of Science ®Google Scholar
• Francone OL, Royer L, Boucher G, et al. Increased cholesterol deposition, expression of scavenger receptors, and response to chemotactic factors in Abca1-deficient macrophages. Arterioscler Thromb Vasc Biol 2005;25:1198-205
   PubMed Web of Science ®Google Scholar
• Jian B, de la Llera-Moya M, Ji Y, et al. Scavenger receptor class B type I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors. J Biol Chem 1998;273:5599-606
   PubMed Web of Science ®Google Scholar
• Nieland TJ, Penman M, Dori L, et al. Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI. Proc Natl Acad Sci USA 2002;99:15422-7
   PubMed Web of Science ®Google Scholar
• Favari E, Zanotti I, Zimetti F, et al. Probucol inhibits ABCA1-mediated cellular lipid efflux. Arterioscler Thromb Vasc Biol 2004;24:2345-50
   PubMed Web of Science ®Google Scholar
• Connelly MA, Klein SM, Azhar S, et al. Comparison of class B scavenger receptors, CD36 and scavenger receptor BI (SR-BI), shows that both receptors mediate high density lipoprotein-cholesteryl ester selective uptake but SR-BI exhibits a unique enhancement of cholesteryl ester uptake. J Biol Chem 1999;274:41-7
   PubMed Web of Science ®Google Scholar
• Schmitz G, Fischer H, Beuck M, et al. Dysregulation of lipid metabolism in Tangier monocyte-derived macrophages. Arteriosclerosis 1990;10:1010-19
   PubMedGoogle Scholar
• Cignarella A, Brennhausen B, von Eckardstein A, et al. Differential effects of lovastatin on the trafficking of endogenous and lipoprotein-derived cholesterol in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 1998;18:1322-9
   PubMed Web of Science ®Google Scholar
• Zhang WY, Gaynor PM, Kruth HS. Apolipoprotein E produced by human monocyte-derived macrophages mediates cholesterol efflux that occurs in the absence of added cholesterol acceptors. J Biol Chem 1996;271:28641-6
   PubMed Web of Science ®Google Scholar
• Kruth HS, Skarlatos SI, Gaynor PM, et al. Production of cholesterol-enriched nascent high-density lipoproteins by human monocyte-derived macrophages is a mechanism that contributes to macrophage cholesterol efflux. J Biol Chem 1994;269:24511-18
   PubMed Web of Science ®Google Scholar
• Cignarella A, Engel T, von Eckardstein A, et al. Pharmacological regulation of cholesterol efflux in human monocyte-derived macrophages in the absence of exogenous cholesterol acceptors. Atherosclerosis 2005;179:229-36
   PubMed Web of Science ®Google Scholar
• Von Eckardstein A, Langer C, Engel T, et al. ATP binding cassette transporter ABCA1 modulates the secretion of apolipoprotein E from human monocyte-derived macrophages. FASEB J 2001;15:1555-61
   PubMed Web of Science ®Google Scholar
• Kockx M, Jessup W, Kritharides L. Regulation of endogenous apolipoprotein E secretion by macrophages. Arterioscler Thromb Vasc Biol 2008;28:1060-7
   PubMed Web of Science ®Google Scholar
• Singaraja RR, Fievet C, Castro G, et al. Increased ABCA1 activity protects against atherosclerosis. J Clin Invest 2002;110:35-42
   PubMed Web of Science ®Google Scholar
• Aiello RJ, Brees D, Francone OL. ABCA1-deficient mice: insights into the role of monocyte lipid efflux in HDL formation and inflammation. Arterioscler Thromb Vasc Biol 2003;23:972-80
   PubMed Web of Science ®Google Scholar
• Wang N, Lan D, Chen W, et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 2004;101:9774-9
   PubMed Web of Science ®Google Scholar
• Venkateswaran A, Repa JJ, Lobaccaro JM, et al. Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages – a transcriptional role for specific oxysterols. J Biol Chem 2000;2.75:14700-7
   PubMed Web of Science ®Google Scholar
• Costet P, Luo Y, Wang N, et al. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid receptor. J Biol Chem 2000;275:28240-5
   PubMed Web of Science ®Google Scholar
• Hozoji M, Munehira Y, Ikeda Y, et al. Direct interaction of nuclear liver X receptor-β with ABCA1 modulates cholesterol efflux. J Biol Chem 2008;283:30057-63
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet L, Ranalletta M, Wang N, et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest 2007;117:3900-8
   PubMed Web of Science ®Google Scholar
• Out R, Hoekstra M, Habets K, et al. Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels. Arterioscler Thromb Vasc Biol 2008;28:258-64
   PubMed Web of Science ®Google Scholar
• Vaughan AM, Oram JF. ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL. J Lipid Res 2006;47:2433-43
   PubMed Web of Science ®Google Scholar
• Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008;454:470-7
   PubMed Web of Science ®Google Scholar
• Rader DJ. Mechanisms of disease: HDL metabolism as a target for novel therapies. Nat Clin Pract Cardiovasc Med 2007;4:102-9
   PubMedGoogle Scholar
• deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels – evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 2008;51:2199-211
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zanotti I, Reilly MP, et al. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 2003;108:661-3
   PubMed Web of Science ®Google Scholar
• Wang MD, Franklin V, Marcel YL. In vivo reverse cholesterol transport from macrophages lacking ABCA1 expression is impaired. Arterioscler Thromb Vasc Biol 2007;27:1837-42
   PubMed Web of Science ®Google Scholar
• Wang X, Collins HL, Ranalletta M, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 2007;117:2216-24
   PubMed Web of Science ®Google Scholar
• Zanotti I, Potì F, Pedrelli M, et al. The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential. J Lipid Res 2008;49:954-60
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet L, Welch C, Pagler TA, et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation 2008;118:1837-47
   PubMed Web of Science ®Google Scholar
• Frederiksen KS, Wulff EM, Sauerberg P, et al. Prediction of PPAR-α ligand-mediated physiological changes using gene expression profiles. J Lipid Res 2004;45:592-601
   PubMed Web of Science ®Google Scholar
• Hennuyer N, Tailleux A, Toppier G, et al. PPARα, but not PPARγ, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol 2005;25:1897-902
   PubMed Web of Science ®Google Scholar
• Huang Z, Zhou X, Nicholson AC, et al. Activation of peroxisome proliferator-activated receptor-α in mice induces expression of the hepatic low-density lipoprotein receptor. Br J Pharmacol 2008;155:596-605
   PubMed Web of Science ®Google Scholar
• Fievet C, Fruchart JC, Staels B. Genetically-engineered animals as research models for atherosclerosis: their use for the characterization of PPAR agonists in the treatment of cardiometabolic disorders. Front Biosci 2007;12:4132-56
   PubMed Web of Science ®Google Scholar
• Ciana P, Biserni A, Tatangelo L, et al. A novel peroxisome proliferator-activated receptor responsive element-luciferase reporter mouse reveals gender specificity of peroxisome proliferator-activated receptor activity in liver. Mol Endocrinol 2007;21:388-400
   PubMed Web of Science ®Google Scholar
• Babaev VR, Yancey PG, Ryzhov SV, et al. Conditional knockout of macrophage PPARγ increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2005;25:1647-53
   PubMed Web of Science ®Google Scholar
• Pourcet B, Fruchart JC, Staels B, et al. Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis. Expert Opin Emerg Drugs 2006;11:379-401
   PubMedGoogle Scholar
• Javitt NB. HepG2 cells as a resource for metabolic studies: lipoprotein, cholesterol, and bile acids. FASEB J 1990;4:161-8
   PubMed Web of Science ®Google Scholar